Contents

HUMAN CANCER BIOLOGY

Deciphering the Mechanisms of Tumorigenesis in Human Pancreatic Ductal Epithelial Cells
Zhe Chang, Zhongkui Li, Xiaoyang Wang, Ya’an Kang, Yuhui Yuan, Jiangong Niu, Huamin Wang, Deyali Chatterjee, Jason B. Fleming, Min Li, James L. Abbruzzese, and Paul J. Chiao

SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival
Mohamed Hassanein, Megan D. Hoeksema, Masakazu Shiota, Jun Qian, Bradford K. Harris, Heidi Chen, Jonathan E. Clark, William E. Alborn, Rosana Eisenberg, and Pierre P. Massion

Impact of Tumor Microenvironment and Epithelial Phenotypes on Metabolism in Breast Cancer
Heather Ann Brauer, Liza Makowski, Katherine A. Hoadley, Patricia Casbas-Hernandez, Lindsay J. Lang, Erick Román-Pérez, Monica D’Arcy, Alex J. Freemerman, Charles M. Perou, and Melissa A. Troester

CANCER THERAPY: PRECLINICAL

Sorafenib Inhibits Cell Migration and Stroma-Mediated Bortezomib Resistance by Interfering B-cell Receptor Signaling and Protein Translation in Mantle Cell Lymphoma
Silvia Xargay-Torrent, Mónica López-Guerra, Arnau Montraveta, Ifigenia Saborit-Villarroya, Laia Rosich, Alba Navarro, Patricia Pérez-Galán, Gaël Roué, Elias Campo, and Dolors Colomer

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Xiaofeng Jiang, Jun Zhou, Anita Giobbie-Hurder, Jennifer Wargo, and F. Stephen Hodi

Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
Joan T. Garrett, Cammie R. Sutton, María Gabriela Kuba, Rebecca S. Cook, and Carlos L. Arteaga

The Journal of Clinical and Translational Research iii www.aacrjournals.org

February 1, 2013 • Volume 19 • Number 3

The Journal of Clinical and Translational Research

Contents

Highlights of This Issue 509

SPECIAL FEATURES

CCR Translations

511 Breast Cancer Stem Cells: We’ve Got Them Surrounded
Hasan Korkaya and Max S. Wicha
See article, p. 643

514 A Focus on PD-L1 in Human Melanoma
Peter Hersey and Stuart Gallagher
See article, p. 598

CCR New Strategies

517 New Strategies in Prostate Cancer: Translating Genomics into the Clinic
Himisha Beltran and Mark A. Rubin

CCR Drug Updates

524 Vandetanib for the Treatment of Medullary Thyroid Cancer
Nicole G. Chau and Robert I. Haddad

Molecular Pathways

530 Molecular Pathways: Targeted α-Particle Radiation Therapy
Kwamena E. Baidoo, Kwon Yong, and Martin W. Brechbiel

Perspective

538 Changing the Way We Do Business: Recommendations to Accelerate Biomarker Development in Pancreatic Cancer
Margaret A. Tempero, David Klimstra, Jordan Berlin, Tony Hollingsworth, Paula Kim, Nipun Merchant, Malcolm Moore, Doug Pleskow, Andrea Wang-Gillam, and Andrew M. Lowy

Review

541 Does Microenvironment Contribute to the Etiology of Estrogen Receptor-Negative Breast Cancer?
Mary Helen Barcellos-Hoff
A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal
Giuseppe Floris, Agnieszka Wozniak, Raf Sciot, Haifu Li, Lori Friedman, Thomas Van Looy, Jasmin Wellens, Peter Vermaelen, Christophe M. Deroose, Jonathan A. Fletcher, Maria Debiec-Rychter, and Patrick Schöfﬁski

Impairment of Glioma Stem Cell Survival and Growth by a Novel Inhibitor for Survivin–Ran Protein Complex
Hacer Guvenc, Marat S. Pavlyukov, Kaushal Joshi, Habibe Kurt, Yeshavanth K. Banasawadi-Siddegowda, Ping Mao, Christopher Hong, Ryosuke Yamada, Chang-Hyuk Kwon, Deepak Bhasin, Somsundaram Chettiar, Gaspar Kitange, In-Hee Park, Jann N. Sarkaria, Chenglong Li, Mihail I. Shakhparonov, and Ichiro Nakano

Targeting CXCR1/2 Signiﬁcantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms
See commentary, p. 511

Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

Systemic Administration of a Novel Immune-Stimulatory Pseudovirion Suppresses Lung Metastatic Melanoma by Regionally Enhancing IFN-γ Production
Kotaro Saga, Katsuto Tamai, Takehiko Yamazaki, and Yasufumi Kaneda

Antitumor Activity of Cell-Permeable RUNX3 Protein in Gastric Cancer Cells
Junghhee Lim, Tam Duong, Nga Do, Phuong Do, Jaetaek Kim, Hyuncheol Kim, Wael El-Rifai, H. Earl Ruley, and Daewoong Jo

Effective Assessment of egfR Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing
Fiamma Butilita, Lara Felicioni, Maela Del Gramastro, Giampaolo Filice, Alessia Di Dorigo, Sara Malatesta, Patrizia Viola, Irene Centi, Tommaso D’Antuono, Roberta Zappacosta, Sandra Rosini, Franco Cuccurullo, and Antonio Marchetti

Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression
Éric Lévesque, Shu-Pin Huang, Étienne Audet-Walsh, Louis Lacombe, Bo-Ying Bao, Yves Fradet, Isabelle Laverdière, Murielle Rouleau, Chao-Yuan Huang, Chia-Cheng Yu, Patrick Caron, and Chantal Guilletette

Detection of miR-34a Promoter Methylation in Combination with Elevated Expression of c-Met and β-Catenin Predicts Distant Metastasis of Colon Cancer
Helge Siemens, Jens Neumann, Rene Jackstadt, Ulrich Mansmann, David Horst, Thomas Kirchner, and Heiko Hermeking

γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)

Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma
Kimberley Jones, Frank Vari, Colm Keane, Pauline Crooks, Jamie P. Nourse, Louise A. Seymour, David Gottlieb, David Ritchie, Devinder Gill, and Maher K. Gandhi
A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non–Small Cell Lung Cancer with a KRAS Mutation
Anne-Marie C. Dingemans, Wouter W. Mellema, Harry J.M. Groen, Atie van Wijk, Sjaak A. Burgers, Peter W.A. Kunst, Erik Thunnissen, Danielle A.M. Heideman, and Egbert F. Smit

Correction: Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

ABOUT THE COVER
Cytology specimens may represent the only available material for molecular diagnosis in non–small cell lung cancer patients. When the number of neoplastic cells in these samples is very low in a large excess of nonneoplastic cells, the specimen is usually judged inadequate for mutation analysis with conventional methods. The cover figure shows a cytological smear obtained from a bronchoalveolar lavage with a limited number of tumor cells. Next-generation sequencing can greatly improve the detection of mutations in these cases. For details, see the article by Buttitta and colleagues on page 691 of this issue.